---
title: "Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298917052.md"
description: "A Phase 2 clinical trial has been initiated to investigate the effectiveness of ebribafusp in treating IgA nephropathy, lupus nephritis, and C3 glomerulopathy. This trial is an open-label study aimed at assessing the potential benefits of ebribafusp in these conditions. The trial aims to enroll approximately 100 participants with these kidney diseases to evaluate the drug's efficacy and safety.Ebribafusp is a novel treatment approach that shows promise in targeting these specific kidney disorders."
datetime: "2026-09-14T12:02:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298917052.md)
  - [en](https://longbridge.com/en/news/298917052.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298917052.md)
generator: "portal-rs"
---

# Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

A Phase 2 clinical trial has been initiated to investigate the effectiveness of ebribafusp in treating IgA nephropathy, lupus nephritis, and C3 glomerulopathy. This trial is an open-label study aimed at assessing the potential benefits of ebribafusp in these conditions. The trial aims to enroll approximately 100 participants with these kidney diseases to evaluate the drug's efficacy and safety.Ebribafusp is a novel treatment approach that shows promise in targeting these specific kidney disorders.

### Related Stocks

- [AKBA.US](https://longbridge.com/en/quote/AKBA.US.md)

## Related News & Research

- [Akebia doses first patient in Phase 2 ebribafusp trial for rare complement-mediated kidney diseases](https://longbridge.com/en/news/298915465.md)
- [Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital](https://longbridge.com/en/news/298343412.md)
- [Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead](https://longbridge.com/en/news/298914581.md)
- [VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead](https://longbridge.com/en/news/298920359.md)
- [Why Vera Therapeutics stock is jumping on new kidney drug trial results](https://longbridge.com/en/news/299076533.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**